Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > IPO

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Mar 31, 2021 10:09pm

251 Views

Post# 32920309

RE:RE:RE:RE:IPO

Yes ... I agree that it's on the low side.

But ... China wasn't on anyone's radar and the deal became a cheap win for Nuance and it put cash in the bank for ATE. A win-win at the right time for us.

We know that this gets more expensive going forward.

-----

(Also ... not just the $ but the value of the royalties)

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market